Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.24 USD | +1.92% | +8.72% | +12.77% |
Mar. 13 | Sector Update: Health Care Stocks Ease Wednesday Afternoon | MT |
Mar. 13 | CorMedix Remains Encouraged on DefenCath Opportunity, RBC Says | MT |
Financials (USD)
Sales 2024 * | 25.16M | Sales 2025 * | 81.93M | Capitalization | 233M |
---|---|---|---|---|---|
Net income 2024 * | -45M | Net income 2025 * | 6M | EV / Sales 2024 * | 11.9 x |
Net Debt 2024 * | 67.4M | Net Debt 2025 * | 48.88M | EV / Sales 2025 * | 3.44 x |
P/E ratio 2024 * |
-5.73
x | P/E ratio 2025 * |
-44.6
x | Employees | 83 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.97% |
Latest transcript on CorMedix Inc.
1 day | +1.92% | ||
1 week | +8.72% | ||
Current month | +19.77% | ||
1 month | +19.77% | ||
3 months | +9.56% | ||
6 months | +14.91% | ||
Current year | +12.77% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Todisco
CEO | Chief Executive Officer | 48 | 22-03-17 |
Mathew David
DFI | Director of Finance/CFO | 47 | 20-05-10 |
Tushar Mukherjee
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Myron Kaplan
CHM | Chairman | 79 | 16-04-26 |
Steven Lefkowitz
DFI | Director of Finance/CFO | 68 | 11-08-14 |
Alan Dunton
BRD | Director/Board Member | 70 | 19-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 36 M€ | +4.92% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 4.24 | +1.92% | 339,828 |
24-03-27 | 4.16 | +1.22% | 379,826 |
24-03-26 | 4.11 | +0.74% | 486,857 |
24-03-25 | 4.08 | +4.08% | 489,686 |
24-03-22 | 3.92 | +0.51% | 381,421 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.77% | 233M | |
+13.52% | 9.63B | |
-7.87% | 5.37B | |
+12.50% | 4.28B | |
+18.09% | 3.71B | |
+42.95% | 2.91B | |
-19.01% | 2.54B | |
-20.66% | 2.37B | |
+17.86% | 1.87B | |
-0.50% | 1.64B |